London, UK; Brentwood, TN; 1 October 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that, on 28 September 2007, in accordance with paragraph 3.1.2 of the FSA Disclosure and Transparency Rules, the Company received notification that, on 28 September 2007, Garry Watts, Non-executive Director of Protherics, acquired 40,000 ordinary 2p shares in the Company (" Ordinary Shares”) at a price of 48.42 pence per share.
